Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Stockholm
  • Sector: Financials
  • Industry: Asset Management
  • Sub-Industry: Private Equity

Karolinska Development AB

+ Add to Watchlist

KDEV:SS

11.6500 SEK 0.1000 0.85%

As of 11:32:49 ET on 05/29/2015.

Snapshot for Karolinska Development AB (KDEV)

Open: 11.5000 Day's Range: 11.3000 - 11.7000 Volume: 28,157
Previous Close: 11.7500 52wk Range: 9.9000 - 25.0000 1-Yr Rtn: -51.66%

Stock Chart for KDEV

No chart data available.
  • KDEV:SS 11.6500
  • 1D
  • 1M
  • 1Y
11.7500
Interactive KDEV Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KDEV

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. OMX -
Earnings Per Share (SEK) (ttm) -12.5460
Est. EPS (SEK) (12/2015) -6.2000
Est. PEG Ratio -
Market Cap (M SEK) 621.93
Shares Outstanding (M) 51.88
30 Day Average Volume 55,703
Price/Book (mrq) 0.3376
Price/Sale (ttm) 106.0780
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/26/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KDEV

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for KDEV

Karolinska Development AB manages a portfolio of life science companies in Europe. The Company's portfolio companies are focused on pharmaceutical development across a broad range of therapeutic areas. Karolinsk's portfolio also encompasses companies developing theranostics as well as medical and formulation technologies.

Jim Van HeusdenChief Executive OfficerTerje KallandDeputy CEO/Chief Scientific Ofcr
Christian TangeChief Financial OfficerUlf RichenbergGeneral Counsel
More Company Profile & Key Executives for KDEV

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil